IPSEN (OTCMKTS:IPSEY) Short Interest Up ? in August

IPSEN (OTCMKTS:IPSEY) saw a significant growth in short interest in August. As of August 14th, there was short interest totaling 1,164 shares, a growth of ? from the July 30th total of 0 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 715 shares, the short-interest ratio is currently 1.6 days.

IPSEN Stock Performance

Shares of OTCMKTS:IPSEY remained flat at $49.15 during trading on Monday. 4 shares of the stock were exchanged, compared to its average volume of 334. IPSEN has a fifty-two week low of $32.02 and a fifty-two week high of $51.10. The business’s 50-day simple moving average is $46.27 and its two-hundred day simple moving average is $46.51.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, Zacks Research raised IPSEN to a “hold” rating in a research note on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).